Results 221 to 230 of about 665,029 (266)
Some of the next articles are maybe not open access.
The tolerability and safety profile of famotidine
Clinical Therapeutics, 1996Famotidine is a specific, long-acting histamine2-receptor antagonist. It is indicated for the treatment of duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Since its introduction for the treatment of acid-related disorders in 1985, an estimated 18.8 million patients worldwide have been treated with ...
C W, Howden, G N, Tytgat
openaire +2 more sources
Safety Profile of Levetiracetam
Epilepsia, 2001Summary: Levetiracetam was approved in November 1999 as add‐on therapy for the treatment of partial‐onset seizures in adults (age 16 years and older). This review focuses on recently published data from four well‐controlled studies in patients with partial‐onset seizures with or without secondary generalization.
openaire +2 more sources
Safety profile of RNAi nanomedicines
Advanced Drug Delivery Reviews, 2012The emerging class of RNA interference (RNAi) therapeutics is a fundamentally novel approach to treating human disease by enabling the pursuit of molecular targets considered "undruggable" by small molecules and traditional protein therapeutics. A key challenge toward realizing the full potential of this technology is the safe and efficient delivery of
Scott A, Barros, Jared A, Gollob
openaire +2 more sources
Safety profile of the quinolones
Journal of Antimicrobial Chemotherapy, 1990The most important finding from preclinical evaluation of fluoroquinolones has been their arthropathogenic potential in young animals. This toxic effect is found with all quinolones known so far and has led to the decision not to use them in children and adolescents, despite the fact that the significance of the effect for humans is still unclear.
openaire +2 more sources
Profiling the safety and tolerability of bisphosphonates
Seminars in Oncology, 2004Because patients with metastatic bone disease suffer a significant burden from their illness and from anticancer treatments, it is therefore important to minimize the side effects of bisphosphonates. The intravenous bisphosphonates, zoledronic acid and pamidronate, have tolerability issues that include a flu-like syndrome, injection-site reactions, and
Body, Jean-Jacques +2 more
openaire +3 more sources
Ziprasidone: profile on safety
Expert Opinion on Pharmacotherapy, 2001Ziprasidone (Geodon, Pfizer) is the latest of a new class of atypical antipsychotics, following the release of clozapine, risperidone, olanzapine and quetiapine. It has a serotonin Type 2a/dopamine Type 2 (5-HT2a/D2) receptor (R) binding ratio of approximately 8:1; amongst the highest of its class.
openaire +2 more sources
Safety and tolerance profile of venlafaxine
International Clinical Psychopharmacology, 1995Venlafaxine has been shown in clinical trials to be safe and well tolerated in patients with major depression. Data were pooled from 19 studies in which 2181 patients were given venlafaxine, 451 were given placebo and 591 were given a reference antidepressant (imipramine, trazodone, clomipramine, maprotiline, dothiepin or amineptine).
P, Danjou, D, Hackett
openaire +2 more sources
Expert Opinion on Drug Safety, 2005
Alefacept is a selective immunomodulating, antipsoriatic drug that blocks the LFA-3/CD2 interaction necessary for the activation and proliferation of memory effector T cells by binding to CD2 expressed on the T cell surface. Because the CD4+ count is reduced by alefacept, it is recommended that this count be monitored on a regular basis to ensure that ...
openaire +2 more sources
Alefacept is a selective immunomodulating, antipsoriatic drug that blocks the LFA-3/CD2 interaction necessary for the activation and proliferation of memory effector T cells by binding to CD2 expressed on the T cell surface. Because the CD4+ count is reduced by alefacept, it is recommended that this count be monitored on a regular basis to ensure that ...
openaire +2 more sources
A review of the safety profile of teicoplanin
Journal of Antimicrobial Chemotherapy, 1991Safety of teicoplanin has been assessed in 3377 patients treated in Europe up to the end of June 1990. One or more adverse events were experienced by 10% of patients. Age and teicoplanin dose had no significant effect on the incidence or type of adverse event.
P G, Davey, A H, Williams
openaire +2 more sources
Drugs, 1993
Ranitidine has been used for the treatment of millions of patients during the past 10 years. A small proportion of patients have developed a reaction to the drug shortly after the start of treatment, usually as a result of 'individual idiosyncrasy'.
openaire +2 more sources
Ranitidine has been used for the treatment of millions of patients during the past 10 years. A small proportion of patients have developed a reaction to the drug shortly after the start of treatment, usually as a result of 'individual idiosyncrasy'.
openaire +2 more sources

